Caris is one of the first laboratories to have a test report optimised for ASCO’s Targeted Agent and Profiling Utilization...
Exclusive partner of Caris Molecular Intelligence in Australia and New Zealand. 
News
Characterising total mutational load in multiple tumour types
The results of two molecular profiling studies provide detailed information on the characteristics of tumours with significant Total Mutational Load (TML)....
Aus and NZ oncologists can provide personalised cancer treatments using Caris Molecular Intelligence
Caris Life Sciences provides the most comprehensive genomic tumour profiling plus (CGP+) of DNA, RNA and proteins enabling personalised therapy...
Caris update from ESMO 2016
Caris Life Sciences has recently passed the milestone of profiling over 100,000 solid tumours using a multiplatform approach. As part...
Caris Present New Outcomes Data from Over 4,700 Profiled Patients at ASCO 2016
At the recent ASCO annual meeting, Caris Life Sciences presented new and important outcomes data from over 4,700 patients that...
Caris presents at 2016 Society of Gynecologic Oncology
At the 2016 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer® recently held in San Diego, Caris Life...
- 1
- 2
Created: February 9, 2017 - Modified: June 28, 2019